Articles les plus consultés

mercredi 4 avril 2018

Acupression pour la douleur menstruelle | EurekAlert! Nouvelles scientifiques

Acupression pour la douleur menstruelle | EurekAlert! Nouvelles scientifiques: Can acupressure achieve a sustained reduction in menstrual pain? Is an app-based self-care program particularly attractive to young women? These questions addressed in a new study by researchers from Charité - Universitätsmedizin Berlin, the results of which have been published in the American Journal of Obstetrics and Gynecology*.

MJ Biotech, Inc Announces $428,000 in First Quarters Sales

MJ Biotech, Inc Announces $428,000 in First Quarters Sales

Cellectar Biosciences Appoints Brian M. Posner as Chief Financial Officer

Cellectar Biosciences Appoints Brian M. Posner as Chief Financial Officer

Cidara Therapeutics to Present Rezafungin Data at the European Congress of Clinical Microbiology and Infectious Diseases 2018 Meeting | Business Wire

Cidara Therapeutics to Present Rezafungin Data at the European Congress of Clinical Microbiology and Infectious Diseases 2018 Meeting | Business Wire: Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that dat

U.S. FDA and European Medicines Agency Accept Regulatory Submissions for Review of Dacomitinib to Treat Metastatic Non-Small Cell Lung Cancer with EGFR-Activating Mutations | Business Wire

U.S. FDA and European Medicines Agency Accept Regulatory Submissions for Review of Dacomitinib to Treat Metastatic Non-Small Cell Lung Cancer with EGFR-Activating Mutations | Business Wire: Pfizer Inc. today announced that the U.S. Food and Drug Administration (FDA) accepted the company’s New Drug Application and granted priority review f

Tonix Pharmaceuticals to Present FDA Breakthrough Therapy-Designated PTSD Program at the MicroCap Conference in New York

Tonix Pharmaceuticals to Present FDA Breakthrough Therapy-Designated PTSD Program at the MicroCap Conference in New York

NICE rejette Dupixent pour une dermatite atopique pour des raisons de coûts, répond Sanofi | Pharmafile

NICE rejette Dupixent pour une dermatite atopique pour des raisons de coûts, répond Sanofi | Pharmafile